RxDoctor Payments Data

Anthony Howard, MD

Internal Medicine · Wrightsville, GANPI 1225102908

Payments from drug & device makers

$1,753in general payments, 2019–2025

Across 89 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$346
  • Pfizer$235
  • AbbVie$196
  • Teva Pharmaceuticals USA, Inc.$162
  • Neurocrine Biosciences, Inc.$137
  • Novo Nordisk$89
  • plus $587 from 17 others

What the payments were for

  • Food & beverage$1,753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,753 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$161
Medicare patients
14
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate22$53,505
OzempicSemaglutide47$47,665
LinzessLinaclotide46$26,250
EliquisApixaban72$25,576
Risperdal ConstaRisperidone Microspheres14$18,305
MounjaroTirzepatide15$16,347
EntrestoSacubitril/Valsartan18$16,338
Risperidone ErRisperidone Microspheres13$15,181
JardianceEmpagliflozin30$12,022
RexultiBrexpiprazole11$11,555
Potassium Chloride396$9,816
TrulicityDulaglutide19$9,344
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen284$8,097
Divalproex Sodium122$6,439
MyrbetriqMirabegron13$5,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$89$47,66547 claims
AbbVieLinzess$196$26,25046 claims
Lilly USA, LLCMounjaro, Trulicity$74$25,69134 claims
PfizerEliquis$235$25,57672 claims
Johnson & JohnsonRisperdal Consta, Xarelto$19$22,82536 claims
NovartisEntresto$13$16,33818 claims
GSKBreo Ellipta$346$4,80111 claims
Sanofi-aventis U.S. LLCRenvela$29$3,28913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Wrightsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →